Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation: A Randomized Controlled Non-inferiority Trial
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
- 试验地点
- 3
- 主要终点
- Medications costs per retrieved oocyte
研究概览
简要总结
The aim of this randomized controlled trial is to compare the efficacy and cost-effectiveness of using progestin with GnRH antagonist to prevent premature LH surge in poor responders undergoing double stimulation protocol.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 35 Years 至 44 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients belonging to Poseidon group 4
排除标准
- •Endometriosis
- •History of recurrent abortion
研究组 & 干预措施
GnRH antagonist group
HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.
In subsequent cycle, frozen embryo transfer was done
干预措施: GnRH antagonist (Drug)
Progestin primed ovarian stimulation group
HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.
In subsequent cycle, frozen embryo transfer was done
干预措施: Progestin primed ovarian stimulation (Drug)
结局指标
主要结局
Medications costs per retrieved oocyte
时间窗: Ten to fifteen days after starting ovarian stimulation]
Total cost of medications used in all cycles/number of retrieved oocytes
次要结局
- Clinical pregnancy rate(5 weeks after embryo transfer])
- Ongoing Pregnancy Rate(18 weeks after embryo transfer])